Welcome to our dedicated page for MeiraGTx Holdings plc Ordinary Shares news (Ticker: MGTX), a resource for investors and traders seeking the latest updates and insights on MeiraGTx Holdings plc Ordinary Shares stock.
MeiraGTx Holdings plc (Nasdaq: MGTX) is a vertically integrated, clinical-stage gene therapy company with a focus on transforming the lives of patients through innovative genetic medicines. Based in London and New York, MeiraGTx pioneers gene therapies for a range of acquired and inherited disorders. The company's research spans serious neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS, as well as ocular diseases like inherited blindness and age-related macular degeneration. Additionally, MeiraGTx is developing treatments for xerostomia, a debilitating side effect of head and neck cancer radiation therapies.
MeiraGTx's product pipeline includes several advanced-stage clinical trials and preclinical research programs aimed at addressing significant unmet medical needs. Key pipeline products include AAV-CNGB3, AAV-CNGA3, and AAV-RPGR. These therapies target eye disorders, central nervous system conditions, and salivary gland dysfunctions.
The company has gained notable recognition and strategic investments from major pharmaceutical entities. Recently, Sanofi made a $30 million strategic investment in MeiraGTx, validating its Riboswitch gene regulation technology and xerostomia program. This investment underscores the broad potential of MeiraGTx's platform, which supports the development of breakthrough medicines for neurodegenerative and immune-mediated diseases.
MeiraGTx is also advancing its gene therapy manufacturing capabilities, with facilities in the United States, the United Kingdom, and the European Union. The company boasts state-of-the-art viral vector design and optimization, as well as a transformative gene regulation platform technology that allows precise, dose-responsive control of gene expression through oral small molecules.
Financially, MeiraGTx is well-positioned with a robust cash balance, strategic partnerships, and a strong pipeline of potential milestone payments. The company recently reported a $50 million milestone payment from Janssen Pharmaceuticals following the initiation of an extension study for the Phase 3 LUMEOS clinical trial for botaretigene sparoparvovec (bota-vec) for X-linked retinitis pigmentosa.
With a dedicated management team and a comprehensive end-to-end manufacturing infrastructure, MeiraGTx is poised to bring innovative genetic therapies to market, addressing both rare and prevalent diseases. For more information, visit www.meiragtx.com.
MeiraGTx Holdings plc (Nasdaq: MGTX) announced two abstract presentations at the ARVO 2023 Annual Meeting. The first presentation covers the humoral immune response data from the Phase 1/2 MGT009 trial of botaretigene sparoparvovec (bota-vec), aimed at treating X-linked retinitis pigmentosa (XLRP) caused by RPGR gene mutations. This therapy is being developed in partnership with Janssen Pharmaceuticals.
The second focus is on AI-assisted engineered promoters to enhance gene expression in rod photoreceptors. Alexandria Forbes, Ph.D., highlighted the importance of these findings for advancing treatment options for XLRP, which currently has no approved therapies. The presentations will take place on April 23 and 27, 2023, at specific sessions.
MeiraGTx Holdings plc (NASDAQ:MGTX) announced that its CEO, Alexandria Forbes, Ph.D., will participate in several upcoming investor conferences. Key events include:
- Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit - April 24, 2023, at 2:30 p.m. ET
- Panel Discussion: Gene Therapy: Positioning for CMC Success - April 25, 2023, at 12:00 p.m. ET
- BofA Securities 2023 Healthcare Conference - May 10, 2023, at 2:35 p.m. PT
- RBC Capital Markets 2023 Global Healthcare Conference - May 17, 2023, at 10:00 a.m. ET
Live webcasts will be accessible on MeiraGTx's Investors page, with replays available for 30 days post-event. MeiraGTx is focused on gene therapy for ocular and neurodegenerative diseases.
MeiraGTx Holdings plc (Nasdaq: MGTX) announced its fourth quarter and full-year financial results for 2022. They reported cash and equivalents of approximately $115 million and a decrease in license revenue from $37.7 million in 2021 to $15.9 million in 2022.
Significant clinical advancements were noted, including positive Phase 1 trial data for AAV-hAQP1 targeting radiation-induced xerostomia and encouraging top-line results from the MGT009 study in X-linked retinitis pigmentosa (XLRP). The company aims for a BLA submission for XLRP in 2024 and plans new trials for both xerostomia and Parkinson's disease.
MeiraGTx Holdings (NASDAQ: MGTX) announced positive clinical results from its Phase 1 AQUAx study of AAV2-hAQP1 for treating radiation-induced xerostomia. Key findings show significant improvements in xerostomia symptoms and saliva flow rates in both unilateral and bilateral cohorts. The therapy demonstrated safety and durability of effects, with improvements lasting up to 3 years. Plans are underway to advance to a Phase 2 study in 2023. Current treatment options for this condition are limited, highlighting a significant unmet need.
FAQ
What is the current stock price of MeiraGTx Holdings plc Ordinary Shares (MGTX)?
What is the market cap of MeiraGTx Holdings plc Ordinary Shares (MGTX)?
What does MeiraGTx Holdings plc specialize in?
Where is MeiraGTx Holdings plc based?
What recent strategic investment did MeiraGTx receive?
What are some key products in MeiraGTx's pipeline?
What was the recent milestone payment MeiraGTx received?
What is MeiraGTx’s Riboswitch gene regulation technology?
What diseases is MeiraGTx targeting with its gene therapies?
What is the significance of the Sanofi investment in MeiraGTx?
Does MeiraGTx have its own manufacturing facilities?
Where can I find more information about MeiraGTx's clinical trials?
